Cilostazol

製品コードS1294 バッチS129401

印刷

化学情報

Chemical Structure Synonyms OPC-13013 Storage
(From the date of receipt)		 3 years -20°C powder
1 years -80°C in solvent
化学式

C20H27N5O2
分子量 369.46 CAS No. 73963-72-1
Solubility (25°C)* 体外 DMSO 74 mg/mL (200.29 mM)
Water Insoluble
Ethanol Insoluble
体内 （毎回新しく調製した物を用意してください）
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明 シロスタゾールは、IC50が0.2 μMである強力なサイクリックヌクレオチドホスホジエステラーゼ3型（PDE3）阻害剤であり、アデノシン取り込み阻害剤です。
in vitro

Cilostazol (OPC-13013) is a 2-oxo-quinoline derivative with antithrombotic, vasodilator, antimitogenic and cardiotonic properties. The vasodilatory and antiplatelet actions of this compound are due mainly to the inhibition of phosphodiesterase 3 (PDE3) and subsequent elevation of intracellular cAMP levels. It inhibits platelet aggregation. This compound also possesses the ability to inhibit adenosine uptake. Elevation of interstitial adenosine by this chemical in the heart is shown to reduce increases in cAMP caused by the PDE3-inhibitory action of cilostazol, thus attenuating the cardiotonic effects. It is reported to inhibit smooth muscle cell proliferation. This agent relaxes vascular smooth muscle and causes vasodilatation. It inhibits the cytokine-induced expression of monocyte chemoattractant protein-1 (MCP-1). This compound reduced plasma triglycerides and raised plasma HDL-cholesterol .

プロトコル(参考用のみ)

参考

  • https://pubmed.ncbi.nlm.nih.gov/10511123/
  • https://pubmed.ncbi.nlm.nih.gov/11830753/
  • https://pubmed.ncbi.nlm.nih.gov/12352320/
  • https://pubmed.ncbi.nlm.nih.gov/12180353/

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Cilostazol-inhibited RhoA/NF-κB signaling mitigates hippocampal inflammation and post-stroke depression [ Front Pharmacol, 2025, 16:1643343] PubMed: 40969943
Propafenone facilitates mitochondrial-associated ferroptosis and synergizes with immunotherapy in melanoma [ J Immunother Cancer, 2024, 12(11)e009805] PubMed: 39581704
Patient-specific iPSC-derived cardiomyocytes reveal variable phenotypic severity of Brugada syndrome [ EBioMedicine, 2023, 95:104741] PubMed: 37544203
Alantolactone induces platelet apoptosis by activating the Akt pathway [ Platelets, 2023, 34(1):2173505] PubMed: 36813739
Multiple PDE3A modulators act as molecular glues promoting PDE3A-SLFN12 interaction and induce SLFN12 dephosphorylation and cell death [ Cell Chem Biol, 2022, S2451-9456(22)00006-X] PubMed: 35104454
GP IIb/IIIa-Mediated Platelet Activation and Its Modulation of the Immune Response of Monocytes Against Candida albicans [ Front Cell Infect Microbiol, 2021, 11:783085] PubMed: 34938671
Carbamazepine Induces Platelet Apoptosis and Thrombocytopenia Through Protein Kinase A [ Front Pharmacol, 2021, 12:749930] PubMed: 34658890
Cilostazol alleviate nicotine induced cardiomyocytes hypertrophy through modulation of autophagy by CTSB/ROS/p38MAPK/JNK feedback loop. [ Int J Biol Sci, 2020, 27;16(11):2001-2013] PubMed: 32398966
Estrogen-Related Hormones Induce Apoptosis by Stabilizing Schlafen-12 Protein Turnover. [ Mol Cell, 2019, 75(6):1103-1116.e9] PubMed: 31420216
PDE3A inhibitor anagrelide activates death signaling pathway genes and synergizes with cell death-inducing cytokines to selectively inhibit cancer cell growth [ Am J Cancer Res, 2019, 9(9):1905-1921] PubMed: 31598394

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。